로딩 중…
지수 로딩 중…
텔콘RF제약
200230· KOSDAQ· Information Technology· Technology Hardware & Equipment
₩1,991-0.05%
2026-11-02
Financials
Valuation Metrics
텔콘RF제약's Market Cap is ₩189B. At end of 2025 it was ₩726B. Ranked #2303 of 2,405 in KR market (top 96%), #1539 of 1,627 on KOSDAQ (top 95%), #234 of 243 in Technology Hardware & Equipment (top 96%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 18.88B KRW | KR#2,303/2,405 Sec#234/243 |
| Revenue | 61.78B KRW | KR#1,679/2,405 Sec#164/243 |
| Net Income | -28.73B KRW | KR—/2,405 Sec—/243 |
| Total Assets | 187.22B KRW | KR#1,361/2,405 Sec#118/243 |
| Net Assets | 99.48B KRW | KR#1,418/2,405 Sec#130/243 |
| Employees | 133 | KR#1,411/2,405 Sec#117/243 |
| Value | ||
| P/B | 0.19x | KR#138/2,405 Sec#7/243 |
| P/S | 0.31x | KR#644/2,405 Sec#58/243 |
| EV/EBITDA | 159.31x | KR#1,515/2,405 Sec#139/243 |
| FCF Yield | 7.13% | KR#762/2,405 Sec#67/243 |
| Profitability | ||
| ROE | -28.87% | KR#2,163/2,405 Sec#219/243 |
| ROA | -15.34% | KR#2,184/2,405 Sec#224/243 |
| Op. Margin | 0.62% | KR#1,542/2,405 Sec#144/243 |
| Revenue Growth | 50.63% | KR#205/2,405 Sec#26/243 |
| Financial Health | ||
| Debt Ratio | 88.19% | KR#1,434/2,405 Sec#158/243 |
| Total Debt | 60.05B KRW | KR#931/2,405 Sec#79/243 |
| FCF | 1.35B KRW | KR#1,123/2,405 Sec#98/243 |
| Cash | 17.46B KRW | KR#1,326/2,405 Sec#130/243 |
| Current Ratio | 0.90x | KR#1,833/2,405 Sec#198/243 |
| Performance | ||
| 1Y Return | -79.06% | KR#2,335/2,405 Sec#235/243 |
| 1M Return | -12.48% | KR#1,381/2,405 Sec#106/243 |
| From 52W High | -81.94% | KR#2,320/2,405 Sec#233/243 |
| 1Y MDD | -81.82% | KR#2,307/2,405 Sec#232/243 |
| Trading | ||
| Volume | 29,003 shares | KR#1,296/2,405 Sec#138/243 |
| Trading Value | 58.5M KRW | KR#1,652/2,405 Sec#177/243 |
| Foreign Own. | 0.00% | KR—/2,405 Sec—/243 |
| Per Share | ||
| EPS | -3,029 KRW | KR—/2,405 Sec—/243 |
| BPS | 10,492 KRW | KR#960/2,405 Sec#85/243 |
Company Info
동사는 1999년 설립되어 RF사업과 완제의약품 제조업을 병행하며 2014년 코스닥에 상장함. 제약·바이오 부문은 KGMP 생산시설을 바탕으로 다양한 제형의 제품을 생산하고 외주생산을 통해 매출 확대 및 신약개발에 투자하고 있음. RF부문은 광 사업장을 확대하며 광전복합 커넥터와 광Cable Ass’y 공급을 통해 광 솔루션 업체로 도약을 준비하고 5G 관련 솔루션 및 동남아시아 시장 진출을 통해 경쟁력 강화에 집중하고 있음. 텔콘RF제약는 1999년에 설립되었으며 경기도 용인시에 본사를 두고 있습니다.